← Motilal Oswal Mutual Fund

Motilal Oswal BSE Healthcare ETF

Index/ETF Data as of Aug 2026 Comparing Jul 2026 → Aug 2026
Share: WhatsApp X
Stocks Held
125
Aug 2026
Equity Holdings
₹44.77 Cr
Equity only, excl. debt & cash
Top 5 Weight
35.2%
Moderate
Top 10 Weight
54.5%
Moderate
Changes
85
0 new · 0 exits
Top Sector
Pharmaceuticals & Biotechnology
77.0% of portfolio
Launch Date
14 Jul 2022
4 years old
📋 What Happened This Month Among existing holdings, Divi's Laboratories Limited saw the biggest increase — now at 7.21% of the portfolio. Max Healthcare Institute Limited was trimmed the most, now at 4.61%. Sun Pharmaceutical Industries Limited remains the top holding with Pharmaceuticals & Biotechnology the dominant sector at 77.0%. ↓ Scroll down for full holdings, sector allocation and month-on-month changes in detail.
Sector Shift Industry allocation month-over-month
Jun 2026 Jul 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 75.6% 75.9% +0.3%
Healthcare Services 23.7% 23.2% -0.4%
Healthcare Equipment & Supplies 0.5% 0.5% 0.0%
Jul 2026 Aug 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 75.9% 77.0% +1.0%
Healthcare Services 23.2% 22.4% -0.8%
Healthcare Equipment & Supplies 0.5% 0.5% 0.0%
Biggest Add
Divi's Laboratories Limited
+0.84% · now 7.21%
Biggest Trim
Max Healthcare Institute Limited
-0.43% · now 4.61%

What Changed in the Portfolio This Month?

Comparing Jul 2026 → Aug 2026

Jul 2026 Aug 2026
↑ 49 Increased ↓ 36 Decreased
#StockSectorJul 2026Aug 2026Change
1
Divi's Laboratories Limited
₹3.23 Cr
Pharmaceuticals & Biotechnology 6.37% 7.21% +0.84%
2
Shilpa Medicare Ltd
₹30.58 L
Pharmaceuticals & Biotechnology 0.45% 0.68% +0.23%
3
Glenmark Pharmaceuticals Limited
₹1.02 Cr
Pharmaceuticals & Biotechnology 2.07% 2.28% +0.21%
4
Neuland Laboratories Limited
₹54.12 L
Pharmaceuticals & Biotechnology 1.01% 1.21% +0.20%
5
IPCA Laboratories Limited
₹75.59 L
Pharmaceuticals & Biotechnology 1.51% 1.69% +0.18%
6
Gland Pharma Limited
₹62.65 L
Pharmaceuticals & Biotechnology 1.23% 1.40% +0.17%
7
Laurus Labs Limited
₹2.01 Cr
Pharmaceuticals & Biotechnology 4.32% 4.47% +0.15%
8
Aurobindo Pharma Limited
₹1.29 Cr
Pharmaceuticals & Biotechnology 2.73% 2.88% +0.15%
9
Morepen Laboratories Limited
₹10.14 L
Pharmaceuticals & Biotechnology 0.12% 0.23% +0.11%
10
Sai Life Sciences Limited
₹54.30 L
Pharmaceuticals & Biotechnology 1.11% 1.21% +0.10%
#StockSectorJul 2026Aug 2026Change
1
Max Healthcare Institute Limited
₹2.07 Cr
Healthcare Services 5.04% 4.61% -0.43%
2
Sun Pharmaceutical Industries Limited
₹5.79 Cr
Pharmaceuticals & Biotechnology 13.32% 12.92% -0.40%
3
Lupin Limited
₹1.45 Cr
Pharmaceuticals & Biotechnology 3.63% 3.23% -0.40%
4
Cipla Limited
₹2.20 Cr
Pharmaceuticals & Biotechnology 5.17% 4.90% -0.27%
5
Torrent Pharmaceuticals Limited
₹1.95 Cr
Pharmaceuticals & Biotechnology 4.52% 4.35% -0.17%
6
Alkem Laboratories Limited
₹86.03 L
Pharmaceuticals & Biotechnology 2.09% 1.92% -0.17%
7
Fortis Healthcare Limited
₹1.30 Cr
Healthcare Services 3.05% 2.89% -0.16%
8
Apollo Hospitals Enterprise Limited
₹2.48 Cr
Healthcare Services 5.67% 5.53% -0.14%
9
Aster DM Healthcare Limited
₹54.78 L
Healthcare Services 1.35% 1.22% -0.13%
10
Biocon Limited
₹79.23 L
Pharmaceuticals & Biotechnology 1.88% 1.77% -0.11%

What Stocks Does This Fund Hold?

125 stocks — Aug 2026

# Stock Sector Cap Weight & Value
1
₹5.79 Cr
Pharmaceuticals & Biotechnology
12.92%
2
₹3.23 Cr
Pharmaceuticals & Biotechnology
7.21%
3
₹2.48 Cr
Healthcare Services
5.53%
4
₹2.20 Cr
Pharmaceuticals & Biotechnology
4.90%
5
₹2.07 Cr
Healthcare Services
4.61%
6
₹2.01 Cr
Pharmaceuticals & Biotechnology
4.47%
7
₹1.95 Cr
Pharmaceuticals & Biotechnology
4.35%
8
₹1.95 Cr
Pharmaceuticals & Biotechnology
4.34%
9
₹1.45 Cr
Pharmaceuticals & Biotechnology
3.23%
10
₹1.30 Cr
Healthcare Services
2.89%
🏆 Top stocks held by Equity funds
See which stocks all active Equity fund managers are buying — ranked by total value invested
🏦 Motilal Oswal Mutual Fund — Portfolio & Holdings
See all funds managed by Motilal Oswal Mutual Fund — conviction stocks, monthly entries & exits

Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.

Found a discrepancy or have feedback? Contact Us — we read every message personally.